Presentation is loading. Please wait.

Presentation is loading. Please wait.

Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells. Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells.

Published byBernard Jennings Modified over 5 years ago

Similar presentations

Presentation on theme: "Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells. Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells."— Presentation transcript:

1 Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells.
Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells. A, Melanoma (HO-1, WM35, and MeWo), breast (MCF-7, MDA-MB-231), and cervical cancer cells (HeLa) were treated for 48 hours with Ad.IL24 (100 pfu per cell) or Ad.vector (100 pfu per cell). Cells were collected, protein purified, and subjected to Western blot analysis to detect phospho-eIF2α protein. B, Cells were treated with Ad.IL24 (100 pfu per cell) or Ad.vector (100 pfu per cell), and cell viability was determined by the MTT proliferation assay 5 days after treatment. Numbers represent the ratio of specific treatments to values in control cells (Ad.vector). C, Cells were treated as described in B, and then assayed for cell death using Annexin V staining a measure of apoptosis, and it was determined 48 hours later by FACS analysis using the CellQuest software (Becton Dickinson). An average of three independent experiments is shown ±SD. Leah Persaud et al. Mol Cancer Res 2017;15: ©2017 by American Association for Cancer Research

Download ppt "Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells. Effect of IL24 on phosphorylation of eIF2α and proliferation in cancer cells."

Similar presentations

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.
Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.

Increase in beige/brown adipocyte characteristics in the xenografts from additional breast cancer cell lines. Increase in beige/brown adipocyte characteristics.
Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.

Fig. 1 LB100 and LB102 specifically inhibit PP2A phosphatase activity and the growth of BCR-ABL+ cells. LB100 and LB102 specifically inhibit PP2A phosphatase.
Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.

Fig. 4 ALRN-6924 inhibits cellular proliferation and clonogenic capacity, and induces cell cycle arrest and apoptosis in AML cell lines. ALRN-6924 inhibits.
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.

Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.
The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.

The p53 pathway is involved in the inhibition of cell proliferation observed in 15-LOX-1-overexpressing cells. The p53 pathway is involved in the inhibition.
Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.

Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.
SW fraction induces S phase arrest and apoptosis.

SW fraction induces S phase arrest and apoptosis.
Ectopic expression of caveolin-1 in ZR75 human breast cancer cells downregulated survivin and decreased cell proliferation. Ectopic expression of caveolin-1.

Ectopic expression of caveolin-1 in ZR75 human breast cancer cells downregulated survivin and decreased cell proliferation. Ectopic expression of caveolin-1.
CYP1A1 knockdown increases cell death.

CYP1A1 knockdown increases cell death.
Induction of apoptosis by NMT siRNAs.

Induction of apoptosis by NMT siRNAs.
A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.

A, B, apoptosis analysis using Annexin V-FITC/PI was done on 5th, 7th, and 9th day after transfection either with si control or si AEBP1in U87MG and U138MG.
The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.

The effects of the FASN blocker C75 on cell growth and survival (A, E, and F), on expression/phosphorylation of PI3K and MAPK signaling proteins and on.
TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.

TFAP2A interacts with HIF-1α and regulates VEGF expression and cell proliferation. TFAP2A interacts with HIF-1α and regulates VEGF expression and cell.
FOXO3a phosphorylation and expression.

FOXO3a phosphorylation and expression.
CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.

CDCP1 is required for invadopodia formation and ECM degradation by human breast cancer cells. CDCP1 is required for invadopodia formation and ECM degradation.
Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

Silencing hOGG1 triggers caspase-3 and caspase-7 activation in response to H2O2 in GM00637 cells. Silencing hOGG1 triggers caspase-3 and caspase-7 activation.

Similar presentations

Ads by Google